Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma.

Ludmila PerelyginaDavid BuchbinderMorna J DorseyMarc EloitFabian HauckTimo HautalaDespina MoshousIgnacio UriarteElena DeripapaJoseph IcenogleKathleen E Sullivan

Published in: Journal of clinical immunology (2019)

Nitazoxanide has limited in vivo anti-viral effects for immunodeficiency-related vaccine-derived rubella. Most patients did not exhibit clinical improvement.

Keyphrases

end stage renal disease
newly diagnosed
sars cov
type diabetes
adipose tissue